vTv Therapeutics (VTVT) IPO Opens 7% Lower

Today's IPO for vTv Therapeutics (NASDAQ: VTVT) opened for trading at $14 after pricing 7,812,500 shares of its Class A common stock at a price to the public of $15 per share, the low end of the expected $15-$17 range.

Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the offering. In addition, Canaccord Genuity Inc. and Janney Montgomery Scott LLC are acting as co-managers for the offering.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

You May Also Be Interested In

• Karman Line Acquisition closes $200M IPO on Nasdaq
• Libra Energy Materials options two Quebec lithium projects near Cisco
• NorthStrive Acquisition prices $100M IPO on Nasdaq